Lakewood-Amedex Biotherapeutics, Inc. (LABT) vs Profusa, Inc. Common Stock (PFSA)

A side-by-side comparison of Lakewood-Amedex Biotherapeutics, Inc. and Profusa, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Lakewood-Amedex Biotherapeutics, Inc. logo
LABT
Lakewood-Amedex Biotherapeutics, Inc.
$1M
$0.85HealthcareDelayed quote: Oct 6, 2026, 2:14 PM EDT
Profusa, Inc. Common Stock logo
PFSA
Profusa, Inc. Common Stock
$2M
$1.71HealthcareDelayed quote: Oct 6, 2026, 2:10 PM EDT

Total return — LABT vs PFSA

growth of $100 · dividends reinvested · last 1y
LABT -99.0% (-99.0%/yr)PFSA -97.1% (-97.1%/yr)PFSA compounded faster over this window
020406080100Start $100$1$3
LABT PFSA

LABT vs PFSA: by the numbers

  • •PFSA is the larger company ($2M vs $1M market cap).

Metrics side by side

Valuation

MetricLABTPFSA
P/B ratio0.34N/A

Profitability

MetricLABTPFSA
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-169.64%N/A
ROIC-163.98%N/A

Go deeper

Full LABT analysisFull PFSA analysisInteractive comparison tool

Dig into the metrics

Lakewood-Amedex Biotherapeutics ROEProfusa, Inc. Common Stock ROELakewood-Amedex Biotherapeutics operating marginProfusa, Inc. Common Stock operating marginLakewood-Amedex Biotherapeutics revenue growthProfusa, Inc. Common Stock revenue growthLakewood-Amedex Biotherapeutics free cash flowProfusa, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.